X
[{"orgOrder":0,"company":"Solve GNE","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"Solve GNE Raises $2.5 Million, Secures Leading Researchers to Help Develop Cure for HIBM","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"},{"orgOrder":0,"company":"Solve GNE","sponsor":"Genosera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Solve GNE and Genosera Sign Agreement to Develop a Novel Bicistronic AAV Gene Therapy Targeting HIBM","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling"}]
Find Clinical Drug Pipeline Developments & Deals by Solve GNE
Filters
Companies By Therapeutic Area
Details:
The funding will be used for a novel Adeno-Associated Virus (AAV) gene therapy, GA-002, aimed at curing GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM).
Lead Product(s):
GA-002
Therapeutic Area: Rare Diseases and Disorders
Product Name: GA-002
Highest Development Status: IND Enabling
Product Type: Cell and Gene therapy
Recipient:
Genosera
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
August 14, 2023
Details:
The net proceeds will be used to support a consortium of academic and private sector researchers tasked with the development of various AAV-based gene therapies to help develop a cure for Hereditary Inclusion Body Myopathy (HIBM).
Lead Product(s):
GA-002
Therapeutic Area: Genetic Disease
Product Name: GA-002
Highest Development Status: IND Enabling
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Undisclosed
Deal Size: $2.5 million
Upfront Cash: Undisclosed
Deal Type: Financing
July 31, 2023